Industry Data Insights provides industry-focused research and analytical intelligence for organizations seeking a clearer view of market performance, competitive conditions, and long-term business opportunities. Through syndicated reports, customized studies, and strategic research support, Industry Data Insights helps businesses access the information needed to evaluate markets and plan for sustainable growth. Our research covers the full market landscape, including industry structure, historical performance, current demand, value-chain developments, regional trends, customer requirements, technological change, and future growth potential. We examine the factors that influence market outcomes, including economic conditions, supply-chain dynamics, policy and regulatory developments, innovation, investment activity, and changing end-user preferences.
At Industry Data Insights, we use a research framework that brings together credible secondary sources, public and company-level information, industry publications, trade statistics, expert perspectives, and data-led market modeling. Our analysts validate key assumptions and assess multiple market variables to develop balanced, actionable conclusions for business leaders, investors, consultants, and product teams. Industry Data Insights supports a broad range of verticals, including industrial manufacturing, engineering, construction, chemicals, energy and power, healthcare, information technology, telecom, automotive, packaging, agriculture, consumer products, retail, and transportation. Each study is structured to help users understand both the immediate market environment and the longer-term forces that may influence demand and competition. From identifying high-potential segments to assessing a competitor’s position or evaluating a new geography, Industry Data Insights delivers research that is designed to be useful, relevant, and aligned with real business questions. Our goal is to turn industry data into strategic direction.
Sep 21 2026
274
.jpeg){kind=small}
Research Associate
Access in-depth insights on industries, companies, trends, and global markets. Our expertly curated reports provide the most relevant data and analysis in a condensed, easy-to-read format.
See the similar reports
| Metric | Value |
|---|---|
| Base Year Valuation (2025) | $3.28 Billion |
| Forecast Valuation (2033) | $5.39 Billion |
| CAGR (2025–2033) | 6.4% |
| Forecast Period | 2025–2033 |
| Largest Regional Market | Asia-Pacific (38.1% share) |
| Dominant Segment | Gelatin enteric empty capsules (58% share) |
The global Enteric Capsules Market is valued at $3.28 billion in 2025 and is projected to reach $5.39 billion by 2033, advancing at a 6.4% CAGR. This growth is fueled by rising demand for oral delivery of acid-sensitive APIs, probiotics, and biologic drugs. The Pharmaceutical Capsules Market overall benefits from a shift toward self-administered therapies, with enteric empty capsules capturing a growing share of oral solid dosage forms.
Key dynamics:
The market recovered from a 2020 contraction of 4.8% caused by delayed elective procedures and reduced clinical trial activity. By 2023, volumes exceeded pre-pandemic levels, and structural shifts toward regional sourcing and vegan capsules persist. Contract manufacturing organizations (CDMOs) now represent 22% of capsule procurement, up from 17% in 2019.
In 2025, enteric empty capsules represent approximately 18% of the total empty capsule market by volume, but 27% by value, reflecting premium pricing for acid-resistant functionality. The Nutraceutical Capsules Market is a key end-use, with probiotic and enzyme products requiring enteric protection accounting for $640 million in 2025 revenue.
Strategic takeaways:
| Segment | CAGR 2025–2033 | 2025 Market Share | Key Demand Driver |
|---|---|---|---|
| Gelatin enteric empty capsules | 5.8% | 58% | Cost efficiency, regulatory acceptance, high mechanical strength |
| HPMC enteric empty capsules | 8.1% | 34% | Vegan/vegetarian demand, low moisture, API stability |
| Pullulan enteric empty capsules | 9.4% | 8% | Clean-label, oxygen barrier, emerging biologics |
The Empty Gelatin Capsules Market remains the largest product sub-segment, generating $1.90 billion in 2025. Gelatin capsules offer superior film-forming properties and lower cost per unit, but face margin pressure from raw material volatility. The HPMC Capsules Market is the fastest-growing, projected to add $720 million in incremental revenue by 2033. HPMC capsules contain no animal derivatives and exhibit lower moisture content, making them preferred for hygroscopic APIs and probiotic formulations.
The Delayed Release Capsules Market is a key application segment, as enteric empty capsules are filled with granules or pellets that need gastric protection. In 2025, delayed release accounted for 71% of enteric empty capsule volume. The remaining 29% is used for immediate-release but acid-sensitive compounds. The Pharmaceutical Capsules Market will continue to absorb most output, but the Nutraceutical Capsules Market is growing at 7.5% CAGR.
| Factor Type | Description | Impact Level | Timeline |
|---|---|---|---|
| Driver | Rising oral biologic candidates requiring enteric protection | High | Long term |
| Driver | Vegan and clean-label consumer demand shifting to HPMC | High | Medium term |
| Driver | Growth in probiotic and enzyme supplements | Medium | Short term |
| Restraint | Gelatin raw material price volatility and supply disruptions | High | Short term |
| Restraint | Stringent regulatory validation for capsule performance | Medium | Long term |
| Restraint | Competition from alternative dosage forms (oral films, tablets) | Medium | Long term |
The primary growth driver is the $1.2 trillion global pharmaceutical pipeline, where 41% of new oral biologic candidates require enteric delivery. The Capsule Coating Market is an adjacent beneficiary, as enteric coatings applied to capsules or tablets depend on consistent polymer performance. The Gelatin Raw Material Market faces a 6.8% annual price increase, squeezing capsule manufacturers that cannot pass costs to customers.
Regulatory developments:
Quantitative evaluation:
The Pharmaceutical Capsules Market is also influenced by track-and-trace regulations, such as the US Drug Supply Chain Security Act (DSCSA), which require serialization and increase compliance costs. In Asia-Pacific, government incentives for local API and excipient manufacturing have increased capsule demand by 11% year-over-year in 2024. Restraints include limited availability of qualified pullulan suppliers and long lead times for HPMC capsule tooling (16–20 weeks).
| Company Name | Core Strength | Target Audience | Market Position |
|---|---|---|---|
| Lonza | High-quality gelatin and HPMC capsules; global regulatory support | Pharmaceutical CDMOs, large pharma | Leader |
| Roquette Frères | Plant-based HPMC and pullulan capsule innovation | Nutraceutical and vegan brands | Leader |
| SUHEUNG | Large-scale gelatin capsule manufacturing; cost leadership | Generic pharma, contract manufacturers | Leader |
| Farmacápsulas | Custom enteric capsule formulations; Latin America footprint | Regional pharma, niche biologics | Challenger |
| Nectar Lifesciences Ltd. | Vertically integrated API and capsule production | Indian and emerging markets | Challenger |
| ZHEJIANG HUILI CAPSULES CO., LTD | High-volume gelatin and HPMC capsules | Export-oriented pharma | Challenger |
| Shaoxing Zhongya Capsule Co., Ltd. | Competitive pricing for standard enteric capsules | Asian generic drug makers | Niche |
| Chemcaps Limited | Specialty enteric coatings and capsule customization | Specialty pharma | Niche |
| Fortcaps | Enteric capsule filling services and small-batch production | Clinical trial sponsors | Niche |
| Natural Capsules Limited | Gelatin and HPMC capsules with US FDA registration | Regulated markets | Challenger |
| Date | Company | Event Type | Impact |
|---|---|---|---|
| 2024 | Lonza | Capacity Expansion | Added 1.2 billion enteric capsule units per year in Europe |
| 2023 | Roquette Frères | Product Launch | Launched pullulan enteric capsules for probiotic delivery |
| 2023 | SUHEUNG | Partnership | Partnered with Indian CDMO to localize HPMC capsule supply |
| 2022 | Farmacápsulas | M&A | Acquired a Brazilian capsule coating firm to integrate enteric technology |
| 2024 | Natural Capsules Limited | Certification | Received US FDA approval for HPMC enteric capsules |
| Region | Projected CAGR (%) | Base Year Valuation (2025) | Primary Catalyst | Regulatory Stringency |
|---|---|---|---|---|
| North America | 5.1% | $0.72 Billion | Biologic oral delivery pipeline | High (FDA, USP) |
| Europe | 5.6% | $0.79 Billion | Vegan capsule mandates | High (EMA, REACH) |
| Asia-Pacific | 7.9% | $1.25 Billion | Cost-effective manufacturing, API growth | Medium (NMPA, CDSCO) |
| LAMEA | 6.8% | $0.52 Billion | Generic drug expansion | Medium (ANVISA, GCC) |
The Capsule Filling Machines Market is expanding in Asia-Pacific due to new capsule lines, while the Capsule Coating Market in North America benefits from advanced enteric polymer formulations.
| Geography | Key Regulation | Recent Change | Compliance Impact |
|---|---|---|---|
| North America | FDA 21 CFR 172.380; USP <711> | DSCSA serialization enforcement (2024) | Higher traceability costs |
| Europe | EMA guideline on enteric coatings; REACH | Titanium dioxide ban in food/pharma (2022) | Reformulation to HPMC |
| Asia-Pacific | NMPA, CDSCO, PMDA | Harmonization with ICH Q3D | Increased testing for elemental impurities |
Major regulatory frameworks for enteric empty capsules include FDA 21 CFR Part 172 for food-contact and pharmaceutical excipients, EMA guidelines on enteric coatings, and ISO 15378 for primary packaging. In Europe, REACH restrictions on titanium dioxide have accelerated the shift to HPMC and pullulan capsules. Asia-Pacific regulators, including NMPA and CDSCO, are harmonizing with ICH Q3D elemental impurity limits, raising testing costs by 8–12% for capsule suppliers. Compliance impacts include increased documentation for gelatin sourcing (BSE/TSE-free certificates) and mandatory serialization under DSCSA. The projected compliance burden will add $0.04–0.06 per capsule unit by 2027.
| Trade Corridor | Net Exporter | Net Importer | Tariff/Trade Barrier | Volume Impact |
|---|---|---|---|---|
| China to North America | China | United States | Section 301 tariffs (25%) | 8% volume reduction in 2024 |
| Europe to Asia-Pacific | Germany, France | India, China | EU GMP certificate requirements | 3% cost increase |
| India to LAMEA | India | Brazil, GCC | MERCOSUR tariffs (10–14%) | 5% price premium |
| South Korea to Global | SUHEUNG | Multiple | FTA benefits | 12% volume growth |
Major global trade corridors for enteric empty capsules run from China, India, and South Korea to North America, Europe, and LAMEA. China is the largest net exporter, shipping 28% of global volume, but faces 25% Section 301 tariffs in the US, reducing 2024 shipment volumes by 8%. India and Brazil benefit from MERCOSUR preferential trade, though non-tariff barriers such as ANVISA inspections add 3–4 weeks to lead times. The Gelatin Raw Material Market is highly traded, with EU and US importers requiring veterinary certificates. Geopolitical tensions and currency fluctuations are projected to increase capsule import costs by 4–6% annually through 2027.
| Aspects | Details |
|---|---|
| Study Period | 2020-2034 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026-2034 |
| Historical Period | 2020-2025 |
| Growth Rate | CAGR of 6.4% from 2020-2034 |
| Segmentation |
|
Our rigorous research methodology combines multi-layered approaches with comprehensive quality assurance, ensuring precision, accuracy, and reliability in every market analysis.
| Stakeholder Role | Interview Share (%) |
|---|---|
| Director of Formulation Development | 25% |
| Capsule Procurement Manager | 20% |
| Regulatory Affairs Lead for Oral Solid Dosage | 20% |
| Supply Chain Director for Pharma Excipients | 15% |
| R&D Scientist | 10% |
| Quality Assurance Manager | 10% |
| Company Type | Representation (%) |
|---|---|
| Enteric Capsule Manufacturers | 35% |
| Pharmaceutical CDMOs | 20% |
| Nutraceutical Brand Owners | 15% |
| Capsule Filling Equipment OEMs | 10% |
| Polymer/Coating Suppliers | 10% |
| Regulatory Affairs Consultants | 10% |
The market contracted by 4.8% in 2020 as elective procedures and clinical trials paused, but recovered to pre-pandemic levels by 2023. Long-term shifts include regional sourcing, with Asia-Pacific now supplying 38.1% of global volume, and a permanent move toward HPMC capsules. Demand from biologic oral dosage forms is projected to grow at 6.4% CAGR through 2033.
Regulatory pressure under EU REACH and CSRD is pushing manufacturers to reduce solvent use and adopt plant-based HPMC or pullulan capsules. Gelatin capsule producers face scrutiny over animal welfare and carbon intensity, with some targets aiming for 30% carbon reduction by 2030. Vegan capsule demand now represents 34% of the market and is growing at 8.1% CAGR.
Approximately 41% of new oral biologic candidates require protection from gastric acid, driving adoption of enteric empty capsules. The global pharmaceutical capsules market is valued at $3.28 billion in 2025 and is forecast to reach $5.39 billion by 2033 at a 6.4% CAGR. Growth is also supported by probiotic and enzyme supplements, which need delayed release for efficacy.
Oral films, 3D-printed tablets, and liquid-filled hard capsules are emerging substitutes, though they currently hold less than 7% of the enteric dosage form market. Enteric coating of tablets remains the largest alternative, accounting for 62% of acid-resistant oral products. Capsule filling machines that support small-batch and personalized dosing may reduce reliance on standard empty capsules.
Gelatin enteric empty capsules hold 58% share, HPMC capsules hold 34%, and pullulan capsules hold 8%. Applications are dominated by pharmaceutical delayed release at 71% of volume, followed by nutraceutical probiotics and enzymes at 22%. The delayed release capsules market is expanding at 7.2% CAGR due to acid-sensitive APIs.
Vegan and vegetarian preferences have increased HPMC capsule purchases by 18% annually since 2022, with 62% of new supplement launches claiming non-animal ingredients. Personalization and direct-to-consumer telehealth drive smaller batch sizes, requiring flexible capsule filling equipment. Price sensitivity remains high, as 44% of buyers in emerging markets prioritize cost over capsule material.
